These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 20013803)

  • 1. Expression and prognostic significance of APAF-1, caspase-8 and caspase-9 in stage II/III colon carcinoma: caspase-8 and caspase-9 is associated with poor prognosis.
    Sträter J; Herter I; Merkel G; Hinz U; Weitz J; Möller P
    Int J Cancer; 2010 Aug; 127(4):873-80. PubMed ID: 20013803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of TRAIL and TRAIL receptors in colon carcinoma: TRAIL-R1 is an independent prognostic parameter.
    Sträter J; Hinz U; Walczak H; Mechtersheimer G; Koretz K; Herfarth C; Möller P; Lehnert T
    Clin Cancer Res; 2002 Dec; 8(12):3734-40. PubMed ID: 12473583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced expression of Apaf-1 in colorectal adenocarcinoma correlates with tumor progression and aggressive phenotype.
    Paik SS; Jang KS; Song YS; Jang SH; Min KW; Han HX; Na W; Lee KH; Choi D; Jang SJ
    Ann Surg Oncol; 2007 Dec; 14(12):3453-9. PubMed ID: 17882496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of ACSS2 expression predicts poor prognosis in patients with gastric cancer.
    Hur H; Kim YB; Ham IH; Lee D
    J Surg Oncol; 2015 Nov; 112(6):585-91. PubMed ID: 26381042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating the Prognostic Role of Elevated Preoperative Carcinoembryonic Antigen Levels in Colon Cancer Patients: Results from the National Cancer Database.
    Becerra AZ; Probst CP; Tejani MA; Aquina CT; González MG; Hensley BJ; Noyes K; Monson JR; Fleming FJ
    Ann Surg Oncol; 2016 May; 23(5):1554-61. PubMed ID: 26759308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impaired CD95 expression predisposes for recurrence in curatively resected colon carcinoma: clinical evidence for immunoselection and CD95L mediated control of minimal residual disease.
    Sträter J; Hinz U; Hasel C; Bhanot U; Mechtersheimer G; Lehnert T; Möller P
    Gut; 2005 May; 54(5):661-5. PubMed ID: 15831912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regularly methylated novel pro-apoptotic genes associated with recurrence in transitional cell carcinoma of the bladder.
    Christoph F; Weikert S; Kempkensteffen C; Krause H; Schostak M; Miller K; Schrader M
    Int J Cancer; 2006 Sep; 119(6):1396-402. PubMed ID: 16642478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of mucinous histology depends on microsatellite instability status in patients with stage III colon cancer treated with adjuvant FOLFOX chemotherapy: a retrospective cohort study.
    Kim SH; Shin SJ; Lee KY; Kim H; Kim TI; Kang DR; Hur H; Min BS; Kim NK; Chung HC; Roh JK; Ahn JB
    Ann Surg Oncol; 2013 Oct; 20(11):3407-13. PubMed ID: 23943026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of CXCR4 and CD133 co-expression on the prognosis of patients with stage II~III colon cancer.
    Li XF; Guo XG; Yang YY; Liu AY
    Asian Pac J Cancer Prev; 2015; 16(3):1073-6. PubMed ID: 25735334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1.
    Chambers SK; Kacinski BM; Ivins CM; Carcangiu ML
    Clin Cancer Res; 1997 Jun; 3(6):999-1007. PubMed ID: 9815777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of APAF-1 expression is associated with early recurrence in stage I, II, and III colorectal cancer.
    Ahn BK; Kim SH; Paik SS; Lee KH
    Langenbecks Arch Surg; 2016 Dec; 401(8):1203-1210. PubMed ID: 27480415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic relevance of estrogen receptor-α Ser167 phosphorylation in stage II-III colon cancer patients.
    López-Calderero I; Carnero A; Astudillo A; Palacios J; Chaves M; Benavent M; Limón ML; Garcia-Carbonero R
    Hum Pathol; 2014 Dec; 45(12):2437-46. PubMed ID: 25283475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TGF-beta receptor 2 downregulation in tumour-associated stroma worsens prognosis and high-grade tumours show more tumour-associated macrophages and lower TGF-beta1 expression in colon carcinoma: a retrospective study.
    Bacman D; Merkel S; Croner R; Papadopoulos T; Brueckl W; Dimmler A
    BMC Cancer; 2007 Aug; 7():156. PubMed ID: 17692120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differentiation of high-risk stage I and II colon tumors based on evaluation of CAV1 gene expression.
    Kitowska A; Wesserling M; Seroczynska B; Szutowicz A; Ronowska A; Peksa R; Pawelczyk T
    J Surg Oncol; 2015 Sep; 112(4):408-14. PubMed ID: 26251082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apoptotic and mitotic indices predict survival rates in lymph node-negative colon carcinomas.
    Sinicrope FA; Hart J; Hsu HA; Lemoine M; Michelassi F; Stephens LC
    Clin Cancer Res; 1999 Jul; 5(7):1793-804. PubMed ID: 10430084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of bcl-2 oncoprotein expression in stage II colon carcinoma.
    Sinicrope FA; Hart J; Michelassi F; Lee JJ
    Clin Cancer Res; 1995 Oct; 1(10):1103-10. PubMed ID: 9815900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expressional STAT3/STAT5 Ratio is an Independent Prognostic Marker in Colon Carcinoma.
    Klupp F; Diers J; Kahlert C; Neumann L; Halama N; Franz C; Schmidt T; Lasitschka F; Warth A; Weitz J; Koch M; Schneider M; Ulrich A
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1548-55. PubMed ID: 25773877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cdc2 as prognostic marker in stage UICC II colon carcinomas.
    Meyer A; Merkel S; Brückl W; Schellerer V; Schildberg C; Campean V; Hohenberger W; Croner RS
    Eur J Cancer; 2009 May; 45(8):1466-73. PubMed ID: 19223178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Independent prognostic value of fascin immunoreactivity in stage III-IV colonic adenocarcinoma.
    Puppa G; Maisonneuve P; Sonzogni A; Masullo M; Chiappa A; Valerio M; Zampino MG; Franceschetti I; Capelli P; Chilosi M; Menestrina F; Viale G; Pelosi G
    Br J Cancer; 2007 Apr; 96(7):1118-26. PubMed ID: 17375048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Overexpression of c-erbB-2 and hypoexpression of nm23 relating to poor prognosis of colorectal carcinoma].
    Zhang JB; Chen L; Han F; Yu L; He S; Zhou JY
    Zhonghua Bing Li Xue Za Zhi; 2003 Apr; 32(2):115-9. PubMed ID: 12839671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.